Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
8161 | 1213 | 48.9 | 90% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | MYELOMA BONE DISEASE | Author keyword | 17 | 70% | 1% | 14 |
2 | CAM DR | Author keyword | 15 | 71% | 1% | 12 |
3 | HEIM | Address | 15 | 88% | 1% | 7 |
4 | JEROME LIPPER MULTIPLE MYELOMA | Address | 13 | 22% | 4% | 54 |
5 | BONE DISEASE | Author keyword | 8 | 14% | 4% | 50 |
6 | MYELOMA THER Y | Address | 5 | 12% | 3% | 41 |
7 | UNIT CELLULAR THER Y | Address | 5 | 33% | 1% | 12 |
8 | CELL ADHESION MEDIATED DRUG RESISTANCE | Author keyword | 5 | 50% | 1% | 7 |
9 | BONE MARROW MICROENVIRONMENT | Author keyword | 4 | 17% | 2% | 23 |
10 | COLLAGEN DERIVED PEPTIDES | Author keyword | 4 | 75% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MYELOMA BONE DISEASE | 17 | 70% | 1% | 14 | Search MYELOMA+BONE+DISEASE | Search MYELOMA+BONE+DISEASE |
2 | CAM DR | 15 | 71% | 1% | 12 | Search CAM+DR | Search CAM+DR |
3 | BONE DISEASE | 8 | 14% | 4% | 50 | Search BONE+DISEASE | Search BONE+DISEASE |
4 | CELL ADHESION MEDIATED DRUG RESISTANCE | 5 | 50% | 1% | 7 | Search CELL+ADHESION+MEDIATED+DRUG+RESISTANCE | Search CELL+ADHESION+MEDIATED+DRUG+RESISTANCE |
5 | BONE MARROW MICROENVIRONMENT | 4 | 17% | 2% | 23 | Search BONE+MARROW+MICROENVIRONMENT | Search BONE+MARROW+MICROENVIRONMENT |
6 | COLLAGEN DERIVED PEPTIDES | 4 | 75% | 0% | 3 | Search COLLAGEN+DERIVED+PEPTIDES | Search COLLAGEN+DERIVED+PEPTIDES |
7 | 5T33 | 2 | 67% | 0% | 2 | Search 5T33 | Search 5T33 |
8 | OSTEOLYTIC BONE DISEASE | 2 | 40% | 0% | 4 | Search OSTEOLYTIC+BONE+DISEASE | Search OSTEOLYTIC+BONE+DISEASE |
9 | SOTATERCEPT | 2 | 43% | 0% | 3 | Search SOTATERCEPT | Search SOTATERCEPT |
10 | SCID HU | 1 | 31% | 0% | 4 | Search SCID+HU | Search SCID+HU |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | C57BL KALWRIJ MOUSE | 27 | 76% | 2% | 19 |
2 | OSTEOLYTIC LESIONS | 27 | 41% | 4% | 51 |
3 | HUMAN MULTIPLE MYELOMA | 25 | 24% | 8% | 92 |
4 | BONE MARROW MICROENVIRONMENT | 23 | 27% | 6% | 73 |
5 | CAM DR | 23 | 52% | 3% | 31 |
6 | INTERLEUKIN 6 SECRETION | 20 | 41% | 3% | 37 |
7 | MALIGNANT PLASMA CELLS | 18 | 40% | 3% | 35 |
8 | MARROW MICROENVIRONMENT | 15 | 49% | 2% | 22 |
9 | RESISTANCE CAM DR | 14 | 42% | 2% | 27 |
10 | MEDIATED DRUG RESISTANCE | 11 | 22% | 4% | 45 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Targeting the bone marrow microenvironment in multiple myeloma | 2015 | 3 | 159 | 26% |
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets | 2007 | 294 | 177 | 32% |
Pathogenesis of myeloma bone disease | 2009 | 98 | 71 | 56% |
The Effects of Bortezomib on Bone Disease in Patients With Multiple Myeloma | 2014 | 5 | 49 | 57% |
Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects | 2012 | 18 | 62 | 66% |
Environment-mediated drug resistance: a major contributor to minimal residual disease | 2009 | 201 | 105 | 25% |
Tumor-host cell interactions in the bone disease of myeloma | 2011 | 18 | 86 | 70% |
Management of bone disease in multiple myeloma | 2014 | 7 | 85 | 41% |
Bone Marrow Microenvironment in Multiple Myeloma Progression | 2012 | 30 | 42 | 40% |
Osteoblast function in myeloma | 2011 | 18 | 52 | 63% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HEIM | 15 | 88% | 0.6% | 7 |
2 | JEROME LIPPER MULTIPLE MYELOMA | 13 | 22% | 4.5% | 54 |
3 | MYELOMA THER Y | 5 | 12% | 3.4% | 41 |
4 | UNIT CELLULAR THER Y | 5 | 33% | 1.0% | 12 |
5 | CLIN THER EUT INTERNAL MED | 3 | 60% | 0.2% | 3 |
6 | U475 | 2 | 15% | 1.2% | 15 |
7 | EXPT THER EUT ONCOL SCI | 2 | 67% | 0.2% | 2 |
8 | UNIT BONE BIOL | 2 | 20% | 0.7% | 9 |
9 | JEROME LIPPER MULTIPLE MYELOMA MED ONCOL | 2 | 25% | 0.6% | 7 |
10 | MYELOMA BRUSSELS | 2 | 26% | 0.5% | 6 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000201721 | PLASMA CELL LEUKEMIA//PRIMARY PLASMA CELL LEUKEMIA//MMSET |
2 | 0.0000160658 | ADAPHOSTIN//BONE MARROW MICROVESSEL DENSITY//PEDIAT PEDIAT ONCOL HEMATOL |
3 | 0.0000118649 | MULTIPLE MYELOMA//LENALIDOMIDE//BORTEZOMIB |
4 | 0.0000095232 | IL 6 RECEPTOR//INTERLEUKIN 6 RECEPTOR//GP130 |
5 | 0.0000088802 | ZOLEDRONIC ACID//SKELETAL RELATED EVENTS//BONE METASTASES |
6 | 0.0000080569 | BORTEZOMIB//PROTEASOME INHIBITOR//PROTEASOME INHIBITORS |
7 | 0.0000064644 | RANKL//OSTEOCLAST//OSTEOCLASTOGENESIS |
8 | 0.0000064352 | SCLEROSTIN//SOST//LRP5 |
9 | 0.0000063379 | IMMUNOFIXATION ELECTROPHORESIS//FREE LIGHT CHAINS//SERUM FREE LIGHT CHAINS |
10 | 0.0000063145 | THALIDOMIDE//CC 5013//CC 4047 |